Immatics Target of Unusually Large Options Trading (NASDAQ:IMTX)

Immatics (NASDAQ:IMTX) saw some unusual options trading on Wednesday. Stock investors acquired 2,279 call options on the stock. This is an increase of approximately 8,665% compared to the average daily volume of 26 call options.

NASDAQ IMTX opened at $13.85 on Thursday. The business has a 50 day simple moving average of $13.16 and a 200 day simple moving average of $12.28. Immatics has a one year low of $9.58 and a one year high of $18.42. The stock has a market capitalization of $871.29 million and a P/E ratio of -7.61.

Immatics (NASDAQ:IMTX) last released its earnings results on Tuesday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $6.25 million during the quarter, compared to analyst estimates of $10.15 million. As a group, sell-side analysts predict that Immatics will post -1.55 earnings per share for the current year.

Several equities research analysts have recently weighed in on IMTX shares. SVB Leerink increased their price target on Immatics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Thursday, July 15th. Zacks Investment Research cut Immatics from a “buy” rating to a “hold” rating in a research note on Friday, August 13th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Immatics in a research note on Wednesday, July 7th.

A number of institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its stake in Immatics by 121.2% in the first quarter. Baker BROS. Advisors LP now owns 3,992,756 shares of the company’s stock valued at $44,759,000 after acquiring an additional 2,187,731 shares during the period. Nantahala Capital Management LLC grew its stake in Immatics by 4.2% in the second quarter. Nantahala Capital Management LLC now owns 2,544,622 shares of the company’s stock valued at $29,543,000 after acquiring an additional 102,857 shares during the period. Redmile Group LLC grew its stake in Immatics by 0.7% in the first quarter. Redmile Group LLC now owns 2,082,814 shares of the company’s stock valued at $23,348,000 after acquiring an additional 14,513 shares during the period. 683 Capital Management LLC grew its stake in Immatics by 8.6% in the first quarter. 683 Capital Management LLC now owns 1,184,045 shares of the company’s stock valued at $13,273,000 after acquiring an additional 94,045 shares during the period. Finally, Woodline Partners LP grew its stake in Immatics by 17.3% in the first quarter. Woodline Partners LP now owns 599,653 shares of the company’s stock valued at $6,722,000 after acquiring an additional 88,397 shares during the period. 33.38% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

See Also: What is a dead cat bounce?

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.